一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | LIU,JIANQIANG | 1281.00 | 14.54 | 不变 | | 中新苏州工业园区创业投资有限公司 | 896.52 | 10.17 | 不变 | | 畅城有限公司 | 612.58 | 6.95 | -120.93 | | 高鹏 | 411.00 | 4.66 | 不变 | | 苏州康诚企业管理咨询服务有限公司 | 353.50 | 4.01 | 不变 | | 霍尔果斯君联承宇创业投资有限公司 | 245.53 | 2.79 | -37.03 | | 玄元私募基金投资管理(广东)有限公司-玄元科新233号私 募证券投资基金 | 199.81 | 2.27 | -0.30 | | 于亦春 | 166.00 | 1.88 | 新进 | | 宁波梅山保税港区同驰投资管理合伙企业(有限合伙) | 116.50 | 1.32 | 不变 | | 上海戊戌资产管理有限公司-戊戌价值15号私募证券投资 基金 | 81.0 ...

Financial Performance - The company's revenue for Q1 2025 was RMB 58,438,952.04, representing a 10.33% increase compared to RMB 52,969,765.80 in the same period last year[3] - The net profit attributable to shareholders was a loss of RMB 3,281,292.00, a decrease of 380.74% from a profit of RMB 1,168,820.49 in the previous year[3] - The basic earnings per share (EPS) was -0.04 RMB, down 479.11% from 0.01 RMB in the same period last year[3] - Total operating revenue for Q1 2025 was CNY 58,438,952.04, an increase of 10.4% compared to CNY 52,969,765.80 in Q1 2024[18] - The net profit for Q1 2025 was a loss of CNY 3,313,077.82, compared to a profit of CNY 1,190,756.45 in Q1 2024, indicating a significant decline in profitability[20] - The operating profit for Q1 2025 was a loss of CNY 1,951,083.79, down from a profit of CNY 2,038,345.06 in Q1 2024[19] Cash Flow - The net cash flow from operating activities was -RMB 34,634,632.56, significantly lower than -RMB 2,277,561.69 in the same period last year[3] - Cash flow from operating activities in Q1 2025 was CNY 69,670,228.34, a decrease from CNY 74,736,111.91 in Q1 2024[22] - The net cash flow from operating activities was -34,634,632.56, a significant decrease compared to -2,277,561.69 from the previous period, indicating a decline in operational efficiency[23] - Cash received from operating activities totaled 72,654,138.33, compared to 82,275,562.79, reflecting a decline in operational cash generation[23] - Cash paid for purchasing goods and services was 61,719,676.18, an increase from 47,638,703.03, indicating rising operational costs[23] Research and Development - Research and development (R&D) expenses totaled RMB 6,792,353.02, a decrease of 34.50% from RMB 10,369,812.18, with R&D expenses accounting for 11.62% of revenue, down 7.95 percentage points[4] - Research and development expenses for Q1 2025 were CNY 6,792,353.02, compared to CNY 10,369,812.18 in Q1 2024, showing a decrease of 34.8%[19] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 946,078,624.97, a decrease of 2.16% from RMB 966,947,228.28 at the end of the previous year[4] - Total liabilities decreased to CNY 86,718,504.63 from CNY 104,440,158.13, reflecting a reduction of approximately 17%[16] - The company's equity attributable to shareholders was CNY 859,642,422.00, slightly down from CNY 862,540,338.57[16] Shareholder Information - The company reported a total of 12,810,000 shares held by the largest shareholder, Liu Jianqiang, representing 14.54% of total shares[10] - The second-largest shareholder, China-Suzhou Industrial Park Venture Capital Co., Ltd., holds 8,965,203 shares, accounting for 10.17%[10] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending activities[11] Future Outlook and Strategies - There are no significant new strategies or product developments mentioned in the conference call[12] - The company has not disclosed any future outlook or performance guidance in the provided documents[12] Investment Activities - Total cash inflow from investment activities was 517,663,809.70, down from 726,841,799.40, reflecting a reduction in investment returns[23] - The net cash flow from investment activities was 13,674,431.84, a decrease from 42,532,266.14, suggesting a slowdown in investment growth[23] - Cash outflow from financing activities totaled 2,585,236.86, compared to 12,430,996.97 in the previous period, indicating a reduction in financing costs[24] - The net cash flow from financing activities was -2,281,518.81, showing a significant decline from -12,430,996.97, which may impact future funding strategies[24] Inventory and Receivables - The company's accounts receivable slightly decreased to ¥102,898,838.48 from ¥108,079,615.10, indicating a reduction of approximately 4.0%[14] - Inventory increased to ¥99,887,672.71, up from ¥85,966,534.06, reflecting a growth of around 16.2%[14]

Financial Performance - The company's operating revenue for 2024 was CNY 298,100,384.74, an increase of 8.90% compared to the previous year[23]. - The net profit attributable to shareholders for 2024 was CNY 17,652,732.43, representing a growth of 14.54% year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 5,944,151.22, a significant increase of 513.96% compared to the previous year[24]. - The net cash flow from operating activities was CNY 22,619,700.00, an increase of 5.32% from the previous year[24]. - Basic and diluted earnings per share for 2024 were CNY 0.20, up from CNY 0.17 in the previous year, marking a 14.72% increase[25]. - The weighted average return on equity was 2.05%, an increase of 0.24 percentage points year-over-year[27]. - The overall gross margin for the reporting period was 40.66%, an increase of 2.48 percentage points compared to the same period last year[45]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.61 per 10 shares to all shareholders, totaling RMB 5,330,869.61, which represents 30.20% of the net profit attributable to shareholders for the year 2024[5]. - The total share capital of the company is 88,129,027 shares, with 737,722 shares excluded from the profit distribution due to being held in a repurchase account[5]. - The company has not conducted any capital reserve transfers to increase share capital or issued bonus shares for the current year[5]. - The cash dividend represents 30.20% of the net profit attributable to the parent company's shareholders for the fiscal year 2024[200]. Research and Development - The company is focusing on the research and development of digital X-ray flat panel detectors and plans to expand into key components such as collimators and high-voltage generators[37]. - R&D expenses for the reporting period were approximately RMB 43.72 million, remaining stable compared to the previous year, with a focus on enhancing R&D efficiency[41]. - The company achieved the authorization of 7 invention patents, 8 utility model patents, and 6 design patents during the reporting period, reflecting its commitment to innovation[41]. - The company has developed a breakthrough DAEC technology that enables automatic control of exposure doses during imaging, enhancing the low-dose advantages of its iodide cesium technology[68]. - The company has made substantial progress in intelligent DR solutions, ensuring high resolution and dynamic range at low doses[89]. - The company is actively investing in the development of unconventional flat panel detectors, CMOS sensors, and advanced imaging technologies, with a long-term focus on integrating smart diagnostic systems[146]. Market Expansion and Sales Strategy - The company is actively expanding its sales channels and personnel in emerging markets such as South America, Asia-Pacific, and the Middle East[39]. - The company has established a global sales and service network covering over 30 countries, enhancing its competitive advantage in international markets[97]. - The company is focusing on optimizing its supply chain and cost control to improve production efficiency and capacity, while also enhancing local assembly and technical service capabilities overseas[145]. - The sales strategy is predominantly direct sales, targeting both domestic and international clients, with plans to expand sales centers in regions like the US, India, Japan, Italy, and South Korea[52]. Corporate Governance - The company has established a strong governance structure with independent directors contributing to oversight[168]. - The management team has been in place since 2017, ensuring stability and continuity in leadership[168]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 852.49 million RMB[172]. - The board of directors held a total of 10 meetings during the year, all conducted via communication methods[177]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the management discussion and analysis section[3]. - The company faced risks from intensified market competition and potential changes in macroeconomic conditions[103]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. Investment and Financial Management - The company plans to invest ¥50 million to establish a wholly-owned subsidiary and ¥30 million to participate in a venture capital fund[135]. - The total investment for the ongoing projects amounts to approximately ¥45.67 million, with a cumulative investment of ¥45.22 million[86]. - The company reported a 32.63% decrease in investment amount from ¥118.74 million to ¥80 million compared to the same period last year[138]. - The company has established a competitive salary mechanism, providing various insurances and housing funds for employees[188].

江苏康众数字医疗科技股份有限公司 鉴证报告 二〇二四年度 关于江苏康众数字医疗科技股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第ZA12164号 江苏康众数字医疗科技股份有限公司全体股东： 我们接受委托，对后附的江苏康众数字医疗科技股份有限公司 （以下简称"贵公司"）2024年度募集资金存放与使用情况专项报告 （以下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 贵公司董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号——上市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15号）、《上海证券交易所科创板 上市公司自律监管指引第1号——规范运作》以及《上海证券交易所 上市公司自律监管指南第1号——公告格式》的相关规定编制募集资 金专项报告。这种责任包括设计、执行和维护与募集资金专项报告编 制相关的内部控制，确保募集资金专项报告真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们 ...

北京市中伦律师事务所 关于江苏康众数字医疗科技股份有限公司 2024 年限制性股票激励计划部分限制性股票作废及 修订激励计划相关事项的 法律意见书 二〇二五年四月 法律意见书 2024 年限制性股票激励计划部分限制性股票作废及修订激励计 划相关事项的法律意见书 致：江苏康众数字医疗科技股份有限公司 北京市中伦律师事务所接受江苏康众数字医疗科技股份有限公司（以下简称 "康众医疗"或"公司"）的委托，担任公司 2024 年限制性股票激励计划（以 下简称"本激励计划"或"本次激励计划"）部分限制性股票作废（以下简称"本 次作废"）及修订激励计划（以下简称"本次修订"）相关事项的专项法律顾问。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券法》）、《上市公司股权激励管理办法》（以下简称《管 理办法》）等有关法律、法规和规范性文件的规定，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对康众医疗提供的有关文件进行了核查和验证， 现出具本法律意见书。 为出具本法律意见书，本所律师根据有关法律、法规、规范性文件的规定和 本所业务规则的要求，本着审慎性及重要性原则 ...

深圳市他山企业管理咨询有限公司 二〇二五年四月 关于江苏康众数字医疗科技股份有限公司 2024 年限制性股票激励计划相关事项的 独立财务顾问报告 | 释 义 | 2 | | --- | --- | | 声 明 | 3 | | 一、本激励计划已履行的必要程序 | 4 | | 二、本次限制性股票作废失效情况 | 6 | | 三、本激励计划修订情况 | 7 | | 四、结论性意见 | 10 | | 五、备查信息 | 11 | 声 明 他山咨询接受委托，担任本激励计划的独立财务顾问并出具本报告，特声明 如下： 深圳市他山企业管理咨询有限公司 独立财务顾问报告 释 义 除非上下文文意另有所指，下列词语具有如下含义： | 康众医疗、公司 | 指 | 江苏康众数字医疗科技股份有限公司 | | --- | --- | --- | | 本激励计划 | 指 | 江苏康众数字医疗科技股份有限公司 2024 年限制性股票 | | | | 激励计划 | | | | 《深圳市他山企业管理咨询有限公司关于江苏康众数字 | | 独立财务顾问报告、本报告 | 指 | 医疗科技股份有限公司 2024 年限制性股票激励计划相关 | | | | 事 ...

江苏康众数字医疗科技股份有限公司 审计报告及财务报表 二○二四年度 江苏康众数字医疗科技股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-4 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-107 | 审 计 报 告 信会师报字[2025]第 ZA12162 号 江苏康众数字医疗科技股份有限公司全体股东： 一、 审计意见 我们审计了江苏康众数字医疗科技股份有限公司（以下简称康众 医疗）财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债 表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有 ...

江苏康众数字医疗科技股份有限公司 内部控制审计报告 二〇二四年度 内部控制审计报告 信会师报字[2025]第 ZA12163 号 江苏康众数字医疗科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了江苏康众数字医疗科技股份有限公司（以下简称 "康众医疗"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是康众医疗董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内控审计报告 第 1 页 我们认为，康众医疗于 2024 年 12 月 31 ...

经中国证券监督管理委员会《关于同意江苏康众数字医疗科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2020]3662号）同意注册，公司向社会公开发行人 民币普通股22,032,257股，每股面值人民币1.00元，每股发行价为人民币23.21元，合计 募集资金人民币511,368,684.97元，扣除各项发行费用（不含税）人民币64,026,198.84元 后，募集资金净额为447,342,486.13元。上述募集资金已全部到位，并由立信会计师事务 所（特殊普通合伙）验证并出具了信会师报字〔2021〕第ZA10069号《验资报告》。 （二）募集资金使用和结余情况 截至2024年12月31日，募集资金的使用情况和结余情况如下： 中信证券股份有限公司 关于江苏康众数字医疗科技股份有限公司 2024 年年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）为江苏康众数字医疗 科技股份有限公司（以下简称"公司"、"康众医疗"）首次公开发行股票并上市的保荐 人。根据《中华人民共和国公司法》《中华人民共和国证券法》《证券发行上市保荐业务管 理办法》《上市公司监管指引第 ...

关于江苏康众数字医疗科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：江苏康众数字医疗科技股份有限公司 审计单位：立信会计师事务所（特殊普通合伙） 联系电话：0512-86860385 江苏康众数字医疗科技股份有限公司 非经营性资金占用及其他关联 资金往来情况的专项报告 二0二四年度 您可使用手机"扫一扫"成进入"注册会计师行业统一监管平台（http://acca.gesp.co）。进行直营 您可使用手机"扫一扫"成进入"注册会计师行业统一监管平台（http://acc、报告编码:沪258238.co 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 为了更好地理解康众医疗 2024 年度非经营性资金占用及其他关 联资金往来情况,汇总表应当与已审计财务报表一并阅读。 关于江苏康众数字医疗科技股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZA12165 号 江苏康众数字医疗科技股份有限公司全体股 ...